NEW DELHI: In a major development, UK’s Covid-19 vaccine has shown similar strong immune response in healthy older adults -aged 56 years and above- to those seen in people between 18 to 55 years, according to findings from a phase-2 trial. The Oxford Covid-19 vaccine has collaborated with Indian drug maker—Serum Institute of India (SII) for which phase 2 clinical trials are being conducted in India also. The findings of the study have been published in the leading medical journal ‘Lancet’.
